Clover’s recombinant SARS-CoV-2 subunit vaccine received emergency use authorisation in China in December last year. Credit: Clover Biopharmaceuticals.

Clover Biopharmaceuticals has launched its recombinant SARS-CoV-2 subunit vaccine, a protein-based Covid-19 vaccine, in China.

The first recombinant SARS-CoV-2 subunit vaccine doses have been delivered and given in Changxing, Zhejiang, as part of the country’s second booster dose (fourth vaccination dose) campaign targeting immuno-compromised people, older adults and those with comorbidities.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In December last year, Clover’s Covid-19 vaccine received emergency use authorisation in the country.

Later, a national immunisation plan for a second booster dose campaign was formally announced by the China National Health Commission (NHC).

It also recommended prioritising specified vaccines, including Clover’s vaccine, which showed better neutralisation against Omicron.

Clover executive director and CEO Joshua Liang said: “We are very proud to be delivering on our commitment to helping protect the elderly and other vulnerable populations with our premium Covid-19 booster vaccine and commencing the launch in Zhejiang province, where our vaccine is manufactured.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company stated that its vaccine achieved 100% efficacy against severe Covid-19 and hospitalisation caused by all SARS-CoV-2 strains in an international Phase II/III clinical trial.

When given as a third dose heterologous booster after two inactivated vaccine doses, Clover’s Covid-19 vaccine showed broad and robust cross-neutralisation of several Omicron subvariants, including Omicron BA.1, BA.2, and BA.5, in a separate Phase III trial.

The company has also commenced launch preparation activities in many strategically prioritised provinces and municipalities, with launches expected in the first quarter of this year.

Based on the production capacity and market dynamics, further expansion in the country is expected to continue throughout the year.

Furthermore, Clover prioritises regulatory submissions in select countries, mainly in Latin America and Asia Pacific.